MedTrace Logo

Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention

NCT06281041 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4657

Last updated 2025-03-14

No results posted yet for this study

Summary

There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve (FFR).

Current nationwide cohort study conducted using Korean National Health Insurance Service database evaluated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis with deferred revascularization based on negative FFR (FFR\>0.80).

Conditions

Interventions

DRUG

Antiplatelet Agents

Aspirin or clopidogrel

Sponsors & Collaborators

  • Chonnam National University

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Joo Myung Lee, MD, MPH, PhD · Samsung Medical Center

  • Danbee Kang, PhD · Samsung Medical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06281041 on ClinicalTrials.gov